Roivant’s experimental lung disease drug mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of patients with pulmonary hypertension associated with interstitial lung disease, the highest PVR reduction reported in a randomized controlled pulmonary hypertension trial, according to a Sept. 8 news release.
Here are five things to know:
- The PHocus trial included 135 patients across 87 sites in 20 countries. Patients received once-daily inhaled mosliciguat or placebo.
- At week 16, pulmonary vascular resistance decreased 51.3% among patients receiving mosliciguat and increased 6.6% among those receiving placebo, resulting in a 56.3% placebo-adjusted reduction.
- Mosliciguat also produced a 35.2-meter placebo-adjusted improvement in six-minute walk distance at week 16.
- NT-proBNP decreased 53.2%, or 357.7 pg/mL, compared with placebo at week 16. Cough was reported in 12.1% of patients receiving mosliciguat and 18.2% of those receiving placebo.
- Pulmovant has initiated the phase 3 PHrontier trial, which is expected to enroll approximately 375 patients worldwide. Mosliciguat is a potential first-in-class, once-daily inhaled soluble guanylate cyclase activator.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
